Virus-Like Particle Engineering: From Rational Design to Versatile Applications.

As mimicking natural virus structures, virus-like particles (VLPs) have evolved to become a widely accepted technology used for humans which are safe, highly efficacious, and profitable. Several remarkable advantages have been achieved to revolutionize the molecule delivery for diverse applications in nanotechnology, biotechnology, and medicine. Here, the rational structure design, manufacturing process, functionalization strategy, and emerging applications of VLPs is reviewed. The situation and challenges in the VLP engineering, the key development orientation, and future applications have been discussed. To develop a good VLP design concept, the virus/VLP-host interactions need to be examined and the screening methods of the VLP stabilization factors need to be established. The functionalization toolbox can be expanded to fabricate smart, robust, and multifunctional VLPs. Novel robust VLP manufacturing platforms are required to deliver vaccines in resource-poor regions with a significant reduction in the production time and cost. The future applications of VLPs are always driven by the development of emerging technologies and new requirements of modern life.

[1]  Kedar G. Patel,et al.  Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. , 2011, Bioconjugate chemistry.

[2]  Thor G. Theander,et al.  Bacterial superglue enables easy development of efficient virus-like particle based vaccines , 2016, Journal of Nanobiotechnology.

[3]  A. Zeltiņš,et al.  Construction and Characterization of Virus-Like Particles: A Review , 2012, Molecular Biotechnology.

[4]  S. Streatfield,et al.  Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development , 2012, Vaccine.

[5]  Bradley C. Bundy,et al.  Efficient disulfide bond formation in virus-like particles. , 2011, Journal of biotechnology.

[6]  Kent Kirshenbaum,et al.  Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the MS2 capsid. , 2006, Nano letters.

[7]  John E. Johnson,et al.  Structures of the native and swollen forms of cowpea chlorotic mottle virus determined by X-ray crystallography and cryo-electron microscopy. , 1995, Structure.

[8]  Pedro Alonso,et al.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. , 2011, The New England journal of medicine.

[9]  R. Wagner,et al.  Virus-like particles—universal molecular toolboxes , 2007, Current Opinion in Biotechnology.

[10]  R. Dagan,et al.  Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. , 1997, The Pediatric infectious disease journal.

[11]  J Huchet,et al.  Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. , 1991, Vaccine.

[12]  R. A. Velez,et al.  Expression of Chikungunya Virus-like Particles , 2012, Microscopy and Microanalysis.

[13]  Nico A J M Sommerdijk,et al.  A virus-based single-enzyme nanoreactor. , 2007, Nature nanotechnology.

[14]  Lin Li,et al.  Use of baculovirus expression system for generation of virus-like particles: Successes and challenges , 2013, Protein Expression and Purification.

[15]  G. Glenn,et al.  Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico , 2011, Vaccine.

[16]  C. Leclerc,et al.  Insect Baculoviruses Strongly Potentiate Adaptive Immune Responses by Inducing Type I IFN1 , 2007, The Journal of Immunology.

[17]  Wei Chan,et al.  Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery , 2015, Proceedings of the National Academy of Sciences.

[18]  Brian J. Ward,et al.  Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza , 2010, PloS one.

[19]  Hiroshi Handa,et al.  Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. , 2014, Virology.

[20]  M G Finn,et al.  RNA-directed packaging of enzymes within virus-like particles. , 2010, Angewandte Chemie.

[21]  Felipe F Casanueva,et al.  Immunization Against Active Ghrelin Using Virus-Like Particles for Obesity Treatment , 2013, Current pharmaceutical design.

[22]  Paul Krugler,et al.  Sortase-Mediated Ligation as a Modular Approach for the Covalent Attachment of Proteins to the Exterior of the Bacteriophage P22 Virus-like Particle. , 2017, Bioconjugate chemistry.

[23]  Thomas R Kreil,et al.  Emerging trends in plasma‐free manufacturing of recombinant protein therapeutics expressed in mammalian cells , 2009, Biotechnology journal.

[24]  James R. Swartz,et al.  Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery , 2017, Bioengineering & translational medicine.

[25]  Gaole Dai,et al.  Disulfide bond: dramatically enhanced assembly capability and structural stability of tobacco mosaic virus nanorods. , 2013, Biomacromolecules.

[26]  V. Mett,et al.  Plants as biofactories. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[27]  Claudia Conte,et al.  VLPs and particle strategies for cancer vaccines , 2013, Expert review of vaccines.

[28]  Sung Soo Han,et al.  Helical plant viral nanoparticles—bioinspired synthesis of nanomaterials and nanostructures , 2017, Bioinspiration & biomimetics.

[29]  Ramamoorthy Ramesh,et al.  Virus-based piezoelectric energy generation. , 2012, Nature nanotechnology.

[30]  Trevor Douglas,et al.  Self-assembling biomolecular catalysts for hydrogen production. , 2016, Nature chemistry.

[31]  Just M. Vlak,et al.  Effective Chikungunya Virus-like Particle Vaccine Produced in Insect Cells , 2013, PLoS neglected tropical diseases.

[32]  V. Yusibov,et al.  Recent progress in the development of plant derived vaccines , 2008, Expert review of vaccines.

[33]  Duane E. Prasuhn,et al.  Unnatural amino acid incorporation into virus-like particles. , 2008, Bioconjugate chemistry.

[34]  Ashley J. Birkett,et al.  Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes , 2004, Infection and Immunity.

[35]  F. Wurm.  Production of recombinant protein therapeutics in cultivated mammalian cells , 2004, Nature Biotechnology.

[36]  Catharina de Lange Davies,et al.  Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles , 2016, Journal of Nanobiotechnology.

[37]  S. Franzen,et al.  Infusion of dye molecules into Red clover necrotic mosaic virus. , 2008, Chemical communications.

[38]  Nicole F Steinmetz,et al.  The art of engineering viral nanoparticles. , 2011, Molecular pharmaceutics.

[39]  Luigi Buonaguro,et al.  Developments in virus-like particle-based vaccines for HIV , 2013, Expert review of vaccines.

[40]  B. Speelman,et al.  Theoretical studies of viral capsid proteins. , 2000, Current opinion in structural biology.

[41]  Ashish Ranjan Sharma,et al.  Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine , 2017, Molecular therapy. Nucleic acids.

[42]  A. Kingsman,et al.  Polyvalent recombinant antigens: a new vaccine strategy. , 1988, Vaccine.

[43]  Juris Jansons,et al.  The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles , 2015, Molecular Biotechnology.

[44]  Min-Chul Kim,et al.  Virus-like particles as universal influenza vaccines , 2012, Expert review of vaccines.

[45]  Dipankar Das,et al.  Efficient production of Tymovirus like particles displaying immunodominant epitopes of Japanese Encephalitis Virus envelope protein. , 2015, Protein expression and purification.

[46]  Natalie K. Connors,et al.  Bioengineering virus‐like particles as vaccines , 2014, Biotechnology and bioengineering.

[47]  Azam Bolhassani,et al.  Different applications of virus‐like particles in biology and medicine: Vaccination and delivery systems , 2015, Biopolymers.

[48]  Jan C M van Hest,et al.  Functionalization of protein-based nanocages for drug delivery applications. , 2014, Nanoscale.